Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

a preliminary proof-of-concept for an all oral, nucleotide combination regimen."Calendar Year 2011 Anticipated Milestones:-- Pharmasset expects to report SVR12 data from its ongoing phase 2b trial with PSI-7977 in HCV genotype 2/3 patients in the second quarter of 2011

-- Pharmasset expects to report the 12 week interim analysis from its PSI-7977 Phase 2b genotype 1 arms in the second quarter of 2011

-- Pharmasset expects to initiate a 24 week Phase 2b trial with PSI-7977 in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2 study with PSI-7977 and PSI-938 in mid-2011

-- Pharmasset plans to file an IND for PSI-661 in the first quarter of 2011 and to initiate a phase 1 trial in the second quarter of 2011

-- Roche expects to initiate INFORM-SVR with RG7128 and RG7227 in the first quarter of 2011

-- Roche expects to initiate a phase 2 study with RG7128 in HCV genotype 2/3 patients in the first half of 2011

-- Roche expects to initiate a phase 3 program with RG7128 in 2011

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strate
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... YORK , May 28, 2015 /PRNewswire/ ... developing new drugs and tests, and this ... the instruments that can assist them. This according ... publisher. Kalorama Information said instruments such as mass ... assist in the identification of drug targets ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ... Officer James H. Mackaness is scheduled to present ... at 9:00 am PT in Los Angeles ... may be accessed on the Event Calendar of the Investors ... of the webcast will be available shortly after the conclusion ...
(Date:5/28/2015)... , May 28, 2015 ... the addition of the "United States Medical ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in the United States ... Medical device manufacturers across the ...
Breaking Medicine Technology:Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3
... -- The,first of two stages of the ... Kamada's Alpha-1 Antitrypsin (AAT) liquid drug,candidate for ... the treatment of patients suffering from AAT,deficiency. ... profiles,and patient tolerability, leading the way to ...
... WIRE)--Jun 1, 2007 - Arrowhead Research,Corporation (Nasdaq:ARWR) ... been published in the 2007 American Society ... The data are from,an ongoing Phase I ... and pharmacokinetics of its lead anti-cancer drug,candidate, ...
Cached Medicine Technology:PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 2PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 3Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... OncLive proudly announces the 2015 Giants of ... a panel of eminent oncologists for landmark achievements that ... be introduced and celebrated TONIGHT at the 3rd Annual ... CDT at The Chicago Illuminating Company, 2110 S. Wabash ... groundbreaking accomplishments, in fields including translational research, gene therapy, ...
(Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
(Date:5/29/2015)... AL (PRWEB) May 29, 2015 ... Fibromyalgia and Chronic Fatigue Syndrome is now offering ... Callers can learn about natural ways to reduce ... low moods, poor sleep, and brain fog. ... weekly Treating and Beating Fibromyalgia call in teleconferences ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... , March 16 MEDNET (MEDNETWorld.com), the ... Health Information Exchange (HIE) solutions, and Hielix, a leader ... healthcare information, today announced the State of North ... complete strategic operational and technical plans for the launch ...
... New chemotherapy agents appear associated with improvements in survival ... substantial cost, according to a report in the March ... one of the JAMA/Archives journals. David H. Howard, ... cancer registry database to measure trends in life expectancy ...
... March 16, 2010 A radiation therapy that uses ... to eliminate the primary tumor and ultimately may improve survival ... UT Southwestern Medical Center physicians who led a national clinical ... the March 17 issue of The Journal of the ...
... News media, scientists and others interested in finance, ... an American Chemical Society (ACS) Small & Medium Business ... you with subject matter experts and global thought leaders ... topics of interest to scientific and engineering professionals. ...
... Fastrack ... Internet based Hosting Solution for HME, Respiratory, Home Infusion Pharmacies and Home Healthcare Agencies. ... Plainview, NY ... for provider’s to convert to their Internet based Hosting Solution for ...
... ... P. Rogers is pleased to present their collection of handmade platform ... living. The nature of a platform bed demands precision in both ... this collection is no exception. Each bed is hand crafted using ...
Cached Medicine News:Health News:MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans 2Health News:MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans 3Health News:Precision radiation therapy may improve survival rates of some lung cancer patients 2Health News:A New Twist On Convert to Purchase 2Health News:Charles P. Rogers Shows Off Their New Platform Bed Collection 2Health News:Charles P. Rogers Shows Off Their New Platform Bed Collection 3Health News:Charles P. Rogers Shows Off Their New Platform Bed Collection 4
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: